Research Article

Predictive Value of Monocyte Chemoattractant Protein-1 in the Development of Diastolic Dysfunction in Patients with Psoriatic Arthritis

Table 2

Clinical and laboratory characteristics of PsA patients classified into groups with respect to the cut-off MCP-1 concentration (347.6 pg/mL).

Patients with serum MCP-1 value
≤347.6 pg/mL ()
Median
25th; 75th percentiles
>347.6 pg/mL ()
Median
25th; 75th percentiles

Clinical characteristics and laboratory parameters
BASDAI3.1 (1.05; 3.94)4 (2.7; 4.95)0.236a
BASFI1.75 (1.1; 2.8)2 (1.35; 5.6)0.19a
DAPSA10.6 (8.3; 18.5)18.45 (11.77; 32.35)0.0000a
BSA (%)0.25 (0; 1)0 (0; 2)0.572a
BMI (kg/m2)26.9 (25.65; 29.9)30.3 (27.15; 33.8)0.082a
Diastolic pressure (mmHg)85 (77.25; 92.75)89.5 (80; 100)0.1a
Systolic pressure (mmHg)129.5 (102; 180)150 (128.75; 159.25)0.01a
CRP (mg/L)1.2 (0.8; 2.8)1.65 (0.95; 9.1)0.249a
Glucose (mmol/L)5.2 (4.9; 5.65)5.8 (5.3; 6.5)0.011a
LDL-cholesterol (mmol/L)3.7 (3; 4.1)4 (3.57; 5.17)0.012a
NT-pro-BNP (pmol/L)60 (35; 136)57 (42; 62.25)0.803a
MCP-1 (pg/L)267.7 (214.2; 299.2)404.1 (391; 422.9)0.00063a
Age (year)61 (54; 64)62 (55.75; 67.25)0.478a
Comorbidities and current therapy ()
Type II diabetes430.503b
Arterial hypertension21140.115b
Cigarette smoking760.210b
sDMARD1370.705b
TNF inhibitors13100.129b
NSAR1730.051b
ACE inhibitors870.155b
Beta blockers1190.123b

MCP-1: Monocyte Chemoattractant Protein-1; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; DAPSA: Disease Activity in Psoriatic Arthritis; BSA: body surface area; BMI: body mass index; NYHA: New York Heart Association Classification; LDL: low-density lipoprotein; NT-pro-BNP: N-terminal probrain natriuretic peptide; sDMARD: synthetic disease-modifying antirheumatic drugs; TNF: tumor necrosis factor; NSAR: nonsteroid antirheumatics; ACE: angiotensin-converting enzyme. Levels of statistical significance are indicated as values in aMann–Whitney test; bChi-squared test.